U izradi stranica "Neplodnost i endokrinologija" korištena je sljedeća literatura:

Kleinstein J. Neue Konzepte der Sterilitätsbehandlung in der täglichen Praxis. Klinik für Reproduktionsmedizin und gynäkologische Endokrinologie, Otto von Guericke Universität Magdeburg, 1997

Oehninger S. Strategies for the Infertile Man. Sem Reproductive Med 2001; 19 (3): 231-237

Moline JM, Golden AL, Bar-Chama N, Smith E, Rauch ME et al. Exposure to hazardous substances and male reproductive health: a research framework. Environ Health Perspect 2000; 108 (9): 803-13

Hageman T. Haidl G. Der Einfluss von Nikotin, Alkohol und Medikamenten/Drogen auf die männliche Fertilität. Reproduktionsmedizin, 2002; 18 (1): 3-6

Oliva A, Spira A, Multigner L. Contribution of environmental factors to the risk of male infertility. Human Reprod 2001; 16 (8): 1768-1776

Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima ST, Coutifaris C. et al. Sperm Morphology, Motility, and Concentration in Fertile and Infertile Men. N Engl J Med 2001, 345 (19):1388-1393

Michelmann HW. Therapie der andrologischen Subfertilität: Sind spermatologische Minimalkriterien sinnvoll? TW Gynäkologie 1996; 9: 186-188

Runnebaum B. Rabe T. Gynäkologische Endokrinologie und Fortpflanzungsmedizin. Band 1 Gynäkologische Endokrinologie. Band 2 Fortpflanzungsmedizin. Springer Verlag Berlin Heidelberg New York 1994.

Graf M. Physiologie des Menstruationszyklus. Gynäkologe 1996; 29:70-83.

Graf M, Distler W. Pathogenese der gestörten Ovarialfunktion. Gynäkologe 1996; 29: 259-267

Windham GC, Elkin E, Fenster L, Waller K, Anderson M, Mitchell PR, Lasley B, Swan S. Ovarian Hormones in Premenopausal Women: Variation by Demographic, Reproductive and Menstrual Cycle Characteristics. Epidemiology 2002; 13 (6): 675-684

Schleußner E, Distler W. Die Therapie der Anovulation mit Antiöstrogenen, Prolaktininhibitoren, Kortikosteroiden und Schilddrüsenhormonen. Gynäkologe 1996; 29: 268-277

Strowitzki T. Ovulationsinduktion mit GnRH und Gonadotropinen. Gynäkologe 1996; 29: 278-283

Ricih-Edwards JW, Spiegelman D, Garland M, Hertzmark e, Hunter DJ, Colditz GA, Willett WC, Wand H, Manson JE. Physical Activity, Body Mass Index, and Ovulatory Disorder Infertility. Epidemiol 2002; 13 (2): 184-190

Diedrich K, Felberbaum R, Baumann P. Assistierte Reproduktion - Ein Überblick. Gynäkologe 1996; 29: 413-419

Rabe T. Neues in der Gynäkologischen Endokrinologie und Fortpflanzungsmedizin. Gynäkologe 2002; 35: 845-860

Ludwig M, Diedrich K. Moderne Aspekte der Reproduktionsmedizin. Gynäkologe 2002; 35: 861-866

Küpker W. Intrazytoplasmatische Spermatozoeninjektion. TW Gynäkologie 1996; 9: 178-185

Al-Hasani S, Ludwig M, Küpker W, fornara P, Diedrich K. Intrazytoplasmatische Spermieninjektion nach MESA oder PESA und TESE. gyn 1996; 1: 58-66

le Hansen M, Kurinczuk JJ, Bower C, Webb S. The Risk of Major Birth Defects after Intracytoplasmic Sperm Injection and in Vitro Fertilization. N Engl J Med 2002; 346: 725-730

Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and Very Low Birth Weight in Infants Conceived with Use of Assisted Reproductive technology. N Engl J Med 2002; 346: 731-737

Baird DD, Wilcox AJ. Kramer MS. Why might infertile couples have problem pregnancies? Commentary. Lancet 1999; 353 (9166)

Loverro G, Vicino M, Lorusso F, Vimercati A, Greco P, Selvaggi L. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow. Gynecol Endocrinol 2001; 15 (2): 142-149

Bröckel J. Interdisziplinäre Stoffwechselproblematik. Hyperandrogenämie, PCOS und Insulinresistenz. T&E Gynäkologie 1998; 186-192

Kleinstein J. Diagnose und Therapie des PCO-Syndromes. Gyn Spectrum 1997; 2: 6-7

Starker W. Therapiekonzepte bei Androgenisierungserscheinungen. Frauenklinik Info, Frauenklinik der FSU Jena, 10/1996

Heard M, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. 2002; 77 (4): 669-673

Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willet WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE. Long or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus. JAMA 2001; 286 (19): 2421-2426

American Society for Reproductive medicine. A Practice Committee Report. The Evaluation and Treatment of Androgen Excess. A Technical Bulletin, April 2000

American Society for Reproductive medicine. A Practice Committee Report. Use of Insulin Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome. A Committee Opinion, April 2000

Karck U. Endometriose. Gynäkologe 1997; 7:581-593

Prentice A. Endometriosis. Regular review. BMJ 2001; 323: 93-95

Valle RF. Endometriosis: current concepts and therapy. Int J Gynecol Obstet 2002; 78: 107-119

Schweppe KW. Endometriose. Diagnose und Klassifikation. TW Gynäkologie 1997, 10:262-268

Bühler K. Endometriose. Medikamentöse Therapie. TW Gynäkologie 1997; 10:271-274

Thomas EJ, Campbell IG. Molecular genetic defects in endometriosis. Gynecol Obstet Invest 2000; 50 Suppl 1: 44-50

Mueller MD, Dreher E, Taylor RN. Auf der Spur eines Rätsels: Angiogenese und Endometriose. Geb Fra 2000; 12: 585-593

Rier SE, Martin DC, Bowman RE, Becker JL. Immunoresponsiveness in Endometriosis. Implications of Estrogenic Toxicants. Environ Health Perspect 1995; 103 (Suppl 7): 151-156

Gleicher N. Immuninsuffizienz - ein potentieller Ansatz für die Behandlung der Endometriose. Br J Obstet Gynecol 1995; 102 (12):4-7

Kiesel L. Endometriose und Immunologie. TW Gynäkologie, 1996; 11:674-675

Schindler AE, Schweppe KW. Endometriose - neue Therapiemöglichkeiten durch Buserelin. Walter de Gruyter Berlin New York 1989.

Kiesel L. Medikamentöse Therapie der Endometriose - Add back verringert Nebenwirkungen. Gyn Spectrum 1996: 2: 6-6

Siebzehnrübl E. Therapie der Endometriose mit einem GnRH-Analogon und gleichzeitiger "Add-back"-Therapie mit Medrogeston. Gyn Spectrum 1997; 2:14-15

Küpker W, Diedrich K. Die assistierte Reproduktion in der Behandlung infertiler Frauen mit Endometriose. Gyn Spectrum 1997; 4:3-5

Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fert Ster 2002; 77 (4): 684-692

Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E, Schindler AE. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gyn Endocrinol 2002; 15 (3): 202-209

Busacca M, Somigliana E, Bianchi S, De Marinis S, Calica C, Candiani M, Vignali M. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum Reprod 2001; 16 (11): 2399-2402

Nishida M, Watanabe K, Sato N, Ichikawa Y. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest 2000; 50 Suppl 1: 18-25

McCluggage WG, Bryson C, Lamki H, Boyle DD. Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy. Int J Gynecol Pathol 2000; 19 (3): 276-9

Zanetta GM, Webb MJ, Keeney GL. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol 2000; 79 (1): 18-22

Fegeler K. Haarausfall bei Frauen. Frauenarzt 1997; 7:1132-1137

Seehafer P. Der Einfluss psychosozialer Faktoren auf das Erleben der Menopause. J Menop 2000; 7 (4): 15-20

Rosemeier HP et al. Zur Qualität von Partnerschaft und Sexualität im Klimakterium. J Menop 1998; 5 (1): 7-12

Rudolf K. Hormonsubstitution im Klimakterium. Der Gynäkologe 1996, 29:315-331

Kuhl H. Metabolische Effekte der Östrogene und Gestagene, Gynäkologe 1997; 30:357-369

Lauritzen C. Richtlinien für die Verschreibung von Östrogenen/Gestagenen in Klimakterium und Postmenopause. Frauenarzt 1997, 4:682-60

Huber J. HRT-Dilemma: Was sollen wir tun? Ärztewoche 2002; 37

Geerlings MI, Ruitenberg A, Witteman CM, van Swieten JC et al. Reproductive Period and Risk of Dementia in Postmenopausal Women, JAMA 2001; 285 (11): 1475-1481

LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone Replacement therapy and Cognition. JAMA 2001; 285 (11): 1489-1499

Birkhäuser MH. Besteht ein Einfluss von Östrogenen auf M. Alzheimer? J Menop 1998; 5 (3): 7-16

Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone Replacement Therapy in Relation to Breast Cancer. JAMA 2002; 287 (6): 734-741

Breckwoldt M. Hormonsubstitution in der Postmenopause und die Wahl des Gestagens. Editorial. Geb Fra 2000, 6:279

Fischl F. die Bedeutung der Gestagene in der modernen Hormonsubstitutionstherapie. H Menop 1998; 5 (Sonderh 1): 16-21

European Progestin Club. Gestagene: Gegenwart und Zukunft. Kongreßbericht. Frauenarzt Forum 1997; 5:2-6

Fletcher SW, Colditz G. Failure of Estrogen Plus Progestin Therapy for Prevention. JAMA 2002; 288 (3) editorial

Heart and Estrogen/Progestin Repplacement Study Follow-up (HERS II). Cardiovascular Disease Outcomes During 6,8 Years of Hormone Therapy. JAMA 2002; 288 (1): 49-57

Heart and Estrogen/Progestin Repplacement Study Follow-up (HERS II). Noncardiovascular Disease Outcomes During 6,8 Years of Hormone Therapy. JAMA 2002; 288 (1): 58-66

Ortmann O, Strowitzki T, Diedrich K. Tibolon in der postmenopausalen Hormonsubstitution: Gewebespezifische Metabolisierung als Therapieprinzip. Frauenarzt, 1999; 4:523-526

Fluck E, File SE, Ramer J. Cognitive Effects of 10 Years of Hormone-Replacement Therapy With Tibolone. J Clin Psychopharmacol 2002; 22 (1): 62-67

Nickelsen T, Harlfinger W. Selektive Östrogenrezeptor-Modulatoren: Eine alternative zur Hormonersatztherapie in der Postmenopause. Frauenarzt; 1999; 6:802-808

Bachmann G, Bancroft J, Braunstein G, Burger H er al. Female androgen insufficiency: the princeton consensus statement on definition, classification and assement. Fert Ster 2002; 77 (4): 660-665

Davis S. Testosterone Deficiency in Women. J Reprod Med 2001; 46: 291-296

Vetrosky DT, Aliabadi Z. The Andropause Debate: Aging Process or Disese State? Clinician Reviews 12 (3): 78-85

Simon JA. Safety of Estrogen/Androgen Regimes. J Reprod Med 2001; 46:281-290

Davis SR, Tran J. Testosterone influences libido and well being in women. Trends Endocrinol Metab 2001; 12 (1): 33-7

Sarrel P, Dobay B, Wiita B. Estrogen and Estrogen-Androgen Replacement in Postmenopausal Women Dissatisfied with Estrogen-Only Therapy: Sexual Behavior and Neuroendocrine Responses. J Reprod Med 1998; 43:847-856

Greendale GA, Espeland M, Slone S, Marcus R, Bareth-Connor E. Bone Mass Response to Discontinuation of Long-term Hormone Replacement Therapy. Arch Intern Med 2002; 162: 665-672

Hollander LE, Freeman EW, Sammel MD, Berlin JA, Grisso JA, Battistini M. Sleep Quality, Estradiol Levels, and Behavioral Factors in Late Reproductive Age Women. Obstet Gynecol 2001; 98 (3):391-397

Ortmann O, Diedrich K, Schultz KD. Hormonelle Substitutionstherapie und gynäkologische Malignome. Frauenarzt 1997, 8:1187-1191

Rabe T. Runnebaum B. Krebs durch Steroidhormone.Vortrag. 1996. Nourypharma Oberschleißheim.

Breckwoldt M. Hormonsubstitution und Mammakarzinom-Risiko. gyn 1997, 2:205-205

Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Maillirad JA et al. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes. J Clin Oncol 2002; 20 (6): 1578-83

Gass MLS, Taylor MB. Alternatives for women through menopause. Am J Obstet Gynecol 2001, Vol 185 (2): 47-56

Han KK, Soares JM, Haidar MA, Rodrigues de Lima G, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99 (3): 389-94

Nagata C, Takatsuka N, Inava S, Kawakami N, Shimizu H. Effect of soymilk consumption on serum estrogen concentrations in premenopausal japanese women. J Natl Cancer Inst 1998; 90 (23): 1830-5

Cassidy A, Bingham s, Setchell KD. Biological effects of a digest of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 1994; 60 (3): 333-40

Martini MC, Dancisak BB, Haggans CJ, Thomas W, Slavin JL. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer 1999; 34 (2): 133-9

Wu AH, Stanczyk FZ, Hendrich S, Murphy PA, Zhang C, Wan P, Pike MC. Effects of soy foods on ovarian function in premenopausal women. Br J Cancer 200; 82 (11): 1879-86

Schulte HM. Osteoporose: Diagnose, Therapie und Prophylaxe. Gynäkologe, 1997; 30:352-356

Steiner E, Grampp S, Imhof H. Densitometrie. State of the Art. Ärzte Zeitung 1995; 09:34-38

Ringe JD. Behandlung der postmenopausalen Osteoporose: Qual der Wahl? hautnah gynäkologie + geburtshilfe 1997, 6:268-271

Schneider HPG, Dören M. Die Behandlung der Osteoporose in der Hand des Gynäkologen. Zentralblatt für Gynäkologie, 1994, 116 (12):691-694

Platen P. Prävention und Therapie der Osteoporose. Deutsches Ärzteblatt, 1997; 94 (49): A2569 - A2574

Wu CH, Yang YC, Yao WJ, Lu FH, Wu JS, Chang CJ. Epidemiological evidence of incresed bone mineral density in habitual tea drinkers. Arch Intern Med 2002; 162 (9): 1001-6

U izradi stranica "Fitohormoni u menopauzi" korištena je sljedeća literatura:

Anderson JW, Johnstone MJ, Cook-Newel MEC. Meta-analysis of the effects of soy protein intake on serum lipids. The New England Journ Med, 1995; 333:276-82.

Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, West L. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. Journal of Clinical Endocrinology and Metabolism 1999; 84(3):895-98.

Hagemeyer, M., W. Banz, T. Winters, and M. Shanahan. Differential effects of phytoestrogens and estrogens on platelet reactivity. Abstract 500.3. FASEB J. 2001; 15 (4): A631.

Banz, W, S. Hauck, B. Gename, A.Bartke, and T. Winters. The effects of the soy phytoestrogens genistein and daidzein on liver function and cardiovascular health. Proceedings of the Sixth World Soybean Research Conference, Global Soy Forum 99, Chicago, IL, Aug.7, pg. 707.

Barrett, J. Phytoestrogens: Friends or foes? Environmental Health Perspectives 1996: 104:478-82.

Hughes, C. Phytochemical mimicry of reproductive hormones and modulation of herbivore fertility by phytoestrogenes. Environmental Health Perspectives 1998: 78:171-75.

M.J. Tikkanen, H. Adlercreutz. Role of the isoflavone of the soya in the prevention of the cardiovascular disease, Bioch Pharm J 2000; 60 (1):1-5.

Middleton, E.Jr. Plant Flavonoid Effects on Mammalian Cell Systems. Herbs, Spices, and Medicinal Plants, 1988; 3: 103-144.

Costello, C. H., and E.V.Lynn. Estrogenic Substances from Plants: Glycyrrhiza Glabra. J Am. Pharmaceutical Soc. 1950;39: 177-180.

Kumagai, A. K. Nishino, T. Kin Shimomura, and Y. Yamamura. Effect of Glycyrrhizin on Estrogen Action Endocrinol. Japan 1967; 14:34-38.

Jarry H Leonhardt S Gorkow C Wuttke W. Agnus Castus Benefits, Exp Clin Endocrinol 1994: 102 (6):448-54.

Raven P., Evert R., Eichorn S., Biology of Plants, W.H.Freeman and Company, New York, 1999.

British Herbal Pharmacopoeia 1989, British Herbal Medicine Association, UK.

Wagner H. Pharmazeutische Biologie, Gustav Fischer Verlag, Stuttgart 1982.

Wagner H, Wiesenauer M. Phytotherapie, Gustav Fischer Verlag, Stutgart, 1995.

Graedon J., Graedon T. Guide to Home and Herbal Remedies, St. Martin's Griffin, New York, 2001.

Bisset, Norman Grainger, ed. Herbal Drugs and Phytopharmaceuticals. Boca Raton, FL: CRC Press, 1994.

Brinker F. Herb Contraindications and Drug Interactions, Sandy, OR: Eclectic Institute, 1997.

Duke J. The Green Pharmacy, St.Martin's Press, New York, 1998.

M. S. Seeling. Interrelationship of magnesium and estrogen in cardiovascular and bone disorders, eclampsia, and premenstrual syndrome, Journal of the American College of Nutrition 1993: 12 (4): 442-458.

web stranice :

www.herbalgram.org - American Botanical Council

www.herbnet.com

www.herbs.org - Herb Research Foundation

www.ars-grin.gov/duke/ - Jim Duke's ethnobotanical database

www.nal.usda.gov/fnic/IBIDS_ - The National Institute of Health

www./herb.com/herbal.htm

www.phytotherapies.org

www.aicr.org - The American Institute for Cancer Research